In contrast, multiple studies using cell-based or various tumor xenograft models of breast cancer have shown a large degree of synergy by combining HSP90 inhibitors with therapies targeting HER2 (such as trastuzumab or lapatinib) [38,39]. This evidence concerns the gene HSP90AA1 and breast carcinoma.